
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics is well-positioned in the growing markets of genetic disorders, infertility, and cell and gene therapy quality control, with its Saphyr system providing a highly sensitive method for genome analysis. The company has a strong cash position of $29.5M and may potentially need to raise additional capital within the next 12 months to fund operations. Risks include lower-than-projected market uptake and the need for further capital raise, but the potential market opportunity and current cash runway make Bionano Genomics a promising investment.
Bears say
Bionano Genomics is seeing declining revenues and increasing net losses, with only a 2.6% YoY decline in revenue for 4Q25 and a 7.4% decline for full-year 2025. Additionally, despite positive developments like the Bionano Symposium and the establishment of new CPT codes, adoption and utilization of the company's OGM technology has been slow, with only modest increases in installations and flowcell sales. The company's financial outlook for 2026 is also not very optimistic, with projected revenue growth of only 16%, leading to an adjusted price target of $6 from $7 per share. Overall, the company's financial performance and slow market adoption of their technology suggest a negative outlook for their stock.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares